1 to 9 of 32 results

Sales of cancer pain therapies set to grow to $5.2 billion in the G7 by 2021


Sales of cancer pain therapies will increase to $5.2 billion in 2021 in leading seven markets (the USA,…

AmgenBiotechnologyDaiichi SankyodenosumabGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRanmarkXgeva

GSK and Daiichi Sankyo set up Japanese vaccines JV


UK pharma giant GlaxoSmithKline (LSE: GSK) says it has signed an agreement with Japan's third-largest…

Asia-PacificDaiichi SankyoGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalVaccines

Daiichi Sankyo and affiliate Ranbaxy restructure global R&D


Japanese drugmaker Daiichi Sankyo and its 64% owned Indian affiliate Ranbaxy Laboratories, as a part…

Daiichi SankyoFinancialGenericsGlaxoSmithKlinePharmaceuticalRanbaxy LaboratoriesResearch

Ranbaxy back in black in fourth quarter as US sales soar


India’s biggest pharmaceutical company Ranbaxy Laboratories has reported a profit of $106m for the…

Astellas PharmaDaiichi SankyoFlomaxGenericsGlaxoSmithKlineGlobalGSKMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSankyoTamsulosin HydrochlorideValacyclovir HydrochlorideValtrex

Big Pharma concludes M&A is not the new R&D


With large firms seeking synergies to drive down R&D costs, merger and acquisition deals can aid in the…

BiotechnologyDaiichi SankyoGeneralGlaxoSmithKlineGlobalGSKLicensingMergers & AcquisitionsPharmaceuticalSankyo

1 to 9 of 32 results

Back to top